Literature DB >> 20727504

Estimating the glomerular filtration rate in obese adult patients for drug dosing.

Manjunath P Pai1.   

Abstract

One-third of adult Americans are currently classified as obese. Physiologic changes associated with obesity can potentially alter the clearance of commonly used drugs. Clearance of certain drugs by the kidneys occurs primarily through glomerular filtration and tubular secretion. Obesity has been associated with glomerular hyperfiltration, whereas obesity-related effects on tubular secretion are not well characterized. Estimation of the glomerular filtration rate (GFR) is currently performed using serum creatinine using the Modification of Diet in Renal Disease (MDRD) equation. However, drug dosing guidelines are often based on creatinine clearance (CLcr) using the Cockcroft-Gault equation as a surrogate of GFR. There is a lack of consensus on the most appropriate method for estimation of GFR or CLcr in patients with obesity. The controversy relates to the use of 2 body size descriptors that confound these equations. The Cockcroft-Gault equation relies on total body weight and so overestimates GFR in patients with obesity. The MDRD equation indexes GFR based on a normalized body surface area, that is, mL/min/1.73 m(2). Conversion of MDRD estimated GFR to non-normalized body surface area overestimates GFR in patients with obesity. The current review explores current approaches and controversies to estimation of GFR and CLcr among obese patients in clinical practice. The role of the alternate body size descriptor, lean body weight to estimate CLcr in obese patients is reviewed. 2010 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20727504     DOI: 10.1053/j.ackd.2010.05.010

Source DB:  PubMed          Journal:  Adv Chronic Kidney Dis        ISSN: 1548-5595            Impact factor:   3.620


  36 in total

1.  Oseltamivir and oseltamivir carboxylate pharmacokinetics in obese adults: dose modification for weight is not necessary.

Authors:  Manjunath P Pai; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

2.  Steady-state plasma pharmacokinetics of oral voriconazole in obese adults.

Authors:  Manjunath P Pai; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2011-03-21       Impact factor: 5.191

3.  Changes in renal function following Roux-en-Y gastric bypass: a prospective study.

Authors:  Jorge L Zelada Getty; Isam N Hamdallah; Hazem N Shamseddeen; Jennifer Wu; Roger K Low; Jacqueline Craig; Mohamed R Ali
Journal:  Obes Surg       Date:  2012-07       Impact factor: 4.129

4.  Amisulpride: Real-World Evidence of Dose Adaptation and Effect on Prolactin Concentrations and Body Weight Gain by Pharmacokinetic/Pharmacodynamic Analyses.

Authors:  Anaïs Glatard; Monia Guidi; Aurélie Delacrétaz; Céline Dubath; Claire Grosu; Nermine Laaboub; Armin von Gunten; Philippe Conus; Chantal Csajka; Chin B Eap
Journal:  Clin Pharmacokinet       Date:  2020-03       Impact factor: 6.447

5.  A modest proposal for improving the accuracy of creatinine-based GFR-estimating equations.

Authors:  Paul L Hebert; Uday S Nori; Udayan Y Bhatt; Lee A Hebert
Journal:  Nephrol Dial Transplant       Date:  2011-03-29       Impact factor: 5.992

6.  Levofloxacin dosing regimen in severely morbidly obese patients (BMI ≥40 kg/m(2)) should be guided by creatinine clearance estimates based on ideal body weight and optimized by therapeutic drug monitoring.

Authors:  Manjunath P Pai; Piergiorgio Cojutti; Federico Pea
Journal:  Clin Pharmacokinet       Date:  2014-08       Impact factor: 6.447

7.  The Daniel K. Inouye College of Pharmacy Scripts: Obesity: The Drug Dose Debate.

Authors:  Cherie Chu; Louis Lteif; Nicole Young
Journal:  Hawaii J Med Public Health       Date:  2017-06

Review 8.  Impact of obesity on drug metabolism and elimination in adults and children.

Authors:  Margreke J E Brill; Jeroen Diepstraten; Anne van Rongen; Simone van Kralingen; John N van den Anker; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2012-05-01       Impact factor: 6.447

9.  Simplified estimation of aminoglycoside pharmacokinetics in underweight and obese adult patients.

Authors:  Manjunath P Pai; Anne N Nafziger; Joseph S Bertino
Journal:  Antimicrob Agents Chemother       Date:  2011-06-13       Impact factor: 5.191

10.  Relationships of Vancomycin Pharmacokinetics to Body Size and Composition Using a Novel Pharmacomorphomic Approach Based on Medical Imaging.

Authors:  Manjunath P Pai; Brian A Derstine; Matt Lichty; Brian E Ross; June A Sullivan; Grace L Su; Stewart C Wang
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.